New research demonstrates value of epigenomic analysis and methylation sequencing capabilities of GuardantINFINITY™ platform for biomarker discovery, therapy selection and response monitoring
PALO ALTO, Calif.--(BUSINESS WIRE)--
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that it will present data from 14 studies highlighting advances in precision oncology and cancer screening at the 2023 American Association for Cancer Research (AACR) Annual Meeting, April 14-19 in Orlando, Florida.
“We look forward to sharing new data at AACR, in particular research demonstrating the tremendous possibilities of epigenomic analysis in biomarker discovery and cancer care,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO. “These presentations show how gaining deeper insights into the tumor microenvironment can help us identify new potential biomarker targets for therapy and predictive markers for treatment resistance, quantify circulating tumor DNA, and contribute to better-informed patient care.”
Multiple studies to be presented at the meeting highlight the new GuardantINFINITY sequencing platform and demonstrate the utility of its methylation sequencing and epigenomic analysis capabilities in biomarker discovery, therapy selection and response monitoring. In particular, studies show that:
-
Methylome sequencing with a liquid-only approach using the GuardantINFINITY platform can quantify circulating tumor DNA level and change with greater sensitivity and precision than genomic sequencing, making longitudinal ctDNA monitoring accessible to a broader range of patients. (Abstract 3123)
-
Cancer genomics alone provides little information on tumor phenotype or functional state, which are governed by epigenetic mechanisms, notably methylation of regulatory regions. The analytical validation of the GuardantINFINITY genomic and epigenomic liquid biopsy platform showed its potential for ultra-sensitive ctDNA detection for minimal residual disease and recurrence surveillance, tumor fraction quantitation for therapy monitoring, oncogenic virus detection, immunogenotyping, epigenotyping, and tumor phenotype characterization, representing a new standard in biomarker discovery. (Abstract 6601)
Full List of Guardant Health Presentations
|
Abstract
|
|
Poster
|
|
Title
|
|
Product
|
|
|
|
|
|
|
|
|
Sunday, April 16 | 1:30 – 5:00 pm
|
|
1052
|
|
29
|
|
Background variability in plasma ctDNA levels in patients with advanced lung cancer in the absence of treatment
|
|
Guardant360®
|
|
|
|
|
|
|
|
|
Monday, April 17 | 9:00 am – 12:30 pm
|
|
LB123
|
|
6
|
|
Poorer outcomes in EGFR L858R-driven NSCLC treated with osimertinib may be addressed with novel combination of BLU-945 and osimertinib
|
|
GuardantINFORM™
|
|
|
|
|
|
|
|
|
Monday, April 17 | 1:30 – 5:00 pm
|
|
3331
|
|
6
|
|
Highly sensitive blood-based multi-cancer screening device with tiered specificity based on diagnostic workflow
|
|
Shield™
|
|
3123
|
|
9
|
|
A method for quantifying circulating tumor DNA level and molecular response using methylome sequencing
|
|
GuardantINFINITY
|
|
3128
|
|
14
|
|
Using Kmerizer, a germline and somatic genotyper for immune associated complex alleles in GuardantINFINITY, for immunotherapy response prediction using cfDNA
|
|
GuardantINFINITY
|
|
3125
|
|
21
|
|
Validation of a bioinformatic model for classifying non-tumor variants in a cell-free DNA liquid biopsy assay
|
|
GuardantINFINITY
|
|
|
|
|
|
|
|
|
Tuesday, April 18 | 1:30 – 5:00 pm
|
|
5573
|
|
30
|
|
Use of circulating tumor DNA (ctDNA) for early assessment of treatment response in patients with non-small cell lung cancer (NSCLC): A real-world (RW) analysis incorporating baseline ctDNA level and molecular response
|
|
GuardantINFORM
|
|
4264
|
|
13
|
|
The genomic landscape of RET fusions in non-small cell lung cancer and the impact of co-occurring genomic alterations on the efficacy of selective RET inhibitors
|
|
Guardant360
|
|
CT278
|
|
18
|
|
ERBB2 amplification detected in ctDNA as a surrogate for tumor tissue FISH analysis of HER2 status in a phase 1 study with zanidatamab for the treatment of locally advanced or metastatic HER2 expressing cancers
|
|
Guardant360
|
|
|
|
|
|
|
|
|
Wednesday, April 19 | 9:00 am – 12:30 pm
|
|
6087
|
|
27
|
|
Mutation and co-mutation landscape of ERBB2 alterations in advanced NSCLC
|
|
Guardant360
|
|
6744
|
|
4
|
|
Cell-free DNA detection of alterations in the MAPK pathway in metastatic hormone receptor positive breast cancer: a multi-institutional analysis of incidence and clinical outcomes
|
|
Guardant360
|
|
6094
|
|
2
|
|
Longitudinal analysis of PARP inhibitor and platinum resistance in BRCA1/2m breast cancer using liquid biopsy
|
|
GuardantINFINITY
|
|
6601
|
|
6
|
|
Analytical validation of a robust integrated genomic and epigenomic liquid biopsy for biomarker discovery, therapy selection, and response monitoring
|
|
GuardantINFINITY
|
|
6603
|
|
8
|
|
BRCA1 promoter methylation in sporadic breast cancer patients detected by liquid biopsy
|
|
GuardantINFINITY
|
The full abstracts for Guardant Health and a list of all abstracts being presented at the meeting can be found at the AACR website here.
For more information and updates from the meeting, follow Guardant Health on LinkedIn and Twitter or visit AACR booth #2465.
About Guardant Health
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360® CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantINFINITY™ tests for advanced-stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. The Guardant Health screening portfolio, including the commercially launched Shield™ test, aims to address the needs of individuals eligible for cancer screening. For more information, visit guardanthealth.com and follow the company on LinkedIn and Twitter.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2022, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.
Source: Guardant Health, Inc.